Cinnamomum Tamala As an Adjuvant Therapy in the Treatment of Major Depressive Disorder: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial With Placebo Control

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share this content! On (X network) By

Cinnamomum Tamala As an Adjuvant Therapy in the Treatment of Major Depressive Disorder: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial With Placebo Control Publisher

Ghaffari S¹ ; Ghobadi A² ; Jamshidi AH² ; Mortazavi SH³ ; Naderi S³ ; Aqamolaei A³ ; Mortezaei A³ ; Sahebolzamani E³ ; Shamabadi A³ ; Jalilvand S³ ; Daraei B⁴ ; Shalbafan MR⁵ ; Akhondzadeh S³

Show Affiliations

1. School of Persian Medicine, Iran University of Medical Sciences, Research Institute for Islamic and Complementory Medicine, Tehran, Iran
2. Research Institute for Islamic and Complementary Medicine, School of Persian Medicine, Iran University of Medical Sciences, Tehran, Iran
3. Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran
4. Department of Toxicology and Pharmacology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Iran
5. Mental Health Research Center, Iran University of Medical Sciences, Tehran, Iran

Source: Advances in Integrative Medicine Published:2020

Abstract

Aim: Major depressive disorder (MDD) is one the most common diseases in the world and about one-third to one-half of the patients don't respond to routine treatment. Thus, the role of alternative medicines, like herbal drugs, is important. The aim of this present randomized, double-blind, placebo-controlled, 6-week trial was to assess the efficacy and tolerability of Cinnamomum tamala as an adjuvant to sertraline in treatment of patients with MDD. Methods: In a randomized double-blind clinical trial, 50 patients diagnosed with major depressive disorder (MDD) based on DSM V, were assigned into two parallel groups to receive sertraline (100 mg twice a day) plus placebo or sertraline (100 mg twice a day) plus Cinnamomum tamala (500 mg daily) for 6 weeks. Patients were evaluated for response to treatment using the HAM-D score at baseline and at weeks 2, 4 and 6. The main outcome measure was to assess the efficacy of C. tamala in improving the MDD symptoms. Results: Forty-two patients completed the trial. Repeated-measure analysis of variance showed a significant effect for time × treatment interaction (Greenhouse-Geisser corrected: F = 5.12, df = 2.19, p-value = 0.006) in HAM-D score. There was significant improvement in HAM-D score of the C. tamala group compared with the placebo group from baseline to weeks 2, 4 and 6. [Ps = 0.012, 0.008 and 0.009; respectively]. The frequency of adverse effects was similar between the two groups. Conclusion: The results of this study suggest that Cinnamomum tamala may be effective as an adjuvant agent in the treatment of MDD. © 2019 Elsevier Ltd

Related Docs

View other Related Docs

1. Advances in Alternative and Integrative Medicine in the Treatment of Depression: A Review of the Evidence, Archives of Iranian Medicine (2021)

2. Palmitoylethanolamide As Adjunctive Therapy in Major Depressive Disorder: A Double-Blind, Randomized and Placebo-Controlled Trial, Journal of Affective Disorders (2018)

3. Comparison of Vortioxetine and Sertraline for Treatment of Major Depressive Disorder in Elderly Patients: A Double-Blind Randomized Trial, Journal of Clinical Pharmacy and Therapeutics (2020)

4. Efficacy of Gemfibrozil As an Adjunct to Sertraline in Major Depressive Disorder, a Double-Blind, Randomized, and Placebo-Controlled Clinical Trial, Iranian Journal of Psychiatry (2021)

5. Citicoline Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Clinical Neuropharmacology (2017)

6. Does Oral Administration of Ketamine Accelerate Response to Treatment in Major Depressive Disorder? Results of a Double-Blind Controlled Trial, Journal of Affective Disorders (2018)

7. L-Carnosine Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Affective Disorders (2020)

8. Ketamine and Other Glutamate Receptor Modulating Agents for Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials, Iranian Journal of Psychiatry (2022)

Experts (# of related papers)

View all Related Experts

Shahin Akhondzadeh Basti (19)

Somaye Arabzadeh (2)

Other Related Docs

9. Cinnamon, a Promising Prospect Towards Alzheimer's Disease, Pharmacological Research (2018)

10. Crocus Sativus L Versus Citalopram in the Treatment of Major Depressive Disorder With Anxious Distress: A Double-Blind, Controlled Clinical Trial, Pharmacopsychiatry (2017)

11. Brain-Derived Neurotrophic Factor Levels in Perinatal Depression: A Systematic Review and Meta-Analysis, Acta Psychiatrica Scandinavica (2023)

12. Herbal Medicine in the Treatment of Primary Dysmenorrhea, Journal of Medicinal Plants (2015)

13. Riluzole for Treatment of Men With Methamphetamine Dependence: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Journal of Psychopharmacology (2019)

14. Efficacy and Safety of Pentoxifylline Combination Therapy in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, International Clinical Psychopharmacology (2021)

15. Electroconvulsive Therapy (Ect) and Aerobic Exercise Training (Aet) Increased Plasma Bdnf and Ameliorated Depressive Symptoms in Patients Suffering From Major Depressive Disorder, Journal of Psychiatric Research (2016)

16. L-Carnosine As an Add-On to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial, Psychiatry Research (2018)

17. Efficacy and Safety of Celecoxib Monotherapy for Mild to Moderate Depression in Patients With Colorectal Cancer: A Randomized Double-Blind, Placebo Controlled Trial, Psychiatry Research (2017)

18. Herbal Medicine for Women's Health, Journal of Medicinal Plants (2015)

19. Cilostazol Adjunctive Therapy in Treatment of Negative Symptoms in Chronic Schizophrenia: Randomized, Double-Blind, Placebo-Controlled Study, Human Psychopharmacology (2017)

20. L-Carnosine As Adjunctive Therapy in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Journal of Child and Adolescent Psychopharmacology (2018)

21. Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study, Journal of Clinical Pharmacy and Therapeutics (2017)

22. Celecoxib for the Treatment of Mild-To-Moderate Depression Due to Acute Brucellosis: A Double-Blind, Placebo-Controlled, Randomized Trial, Journal of Clinical Pharmacy and Therapeutics (2015)

23. St. Johnʼs Wort (Hypericum Perforatum) and Depression: What Happens to the Neurotransmitter Systems?, Naunyn-Schmiedeberg's Archives of Pharmacology (2022)

Style	Citing Format
MLA	Ghaffari S, et al.. "Cinnamomum Tamala As an Adjuvant Therapy in the Treatment of Major Depressive Disorder: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial With Placebo Control." Advances in Integrative Medicine, vol. 7, no. 3, 2020, pp. 141-147.
APA	Ghaffari S, Ghobadi A, Jamshidi AH, Mortazavi SH, Naderi S, Aqamolaei A, Mortezaei A, Sahebolzamani E, Shamabadi A, Jalilvand S, Daraei B, Shalbafan MR, Akhondzadeh S (2020). Cinnamomum Tamala As an Adjuvant Therapy in the Treatment of Major Depressive Disorder: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial With Placebo Control. Advances in Integrative Medicine, 7(3), 141-147.
Chicago	Ghaffari S, Ghobadi A, Jamshidi AH, Mortazavi SH, Naderi S, Aqamolaei A, Mortezaei A, et al.. "Cinnamomum Tamala As an Adjuvant Therapy in the Treatment of Major Depressive Disorder: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial With Placebo Control." Advances in Integrative Medicine 7, no. 3 (2020): 141-147.
Harvard	Ghaffari S et al. (2020) 'Cinnamomum Tamala As an Adjuvant Therapy in the Treatment of Major Depressive Disorder: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial With Placebo Control', Advances in Integrative Medicine, 7(3), pp. 141-147.
Vancouver	Ghaffari S, Ghobadi A, Jamshidi AH, Mortazavi SH, Naderi S, Aqamolaei A, et al.. Cinnamomum Tamala As an Adjuvant Therapy in the Treatment of Major Depressive Disorder: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial With Placebo Control. Advances in Integrative Medicine. 2020;7(3):141-147.
BibTex	@article{ author = {Ghaffari S and Ghobadi A and Jamshidi AH and Mortazavi SH and Naderi S and Aqamolaei A and Mortezaei A and Sahebolzamani E and Shamabadi A and Jalilvand S and Daraei B and Shalbafan MR and Akhondzadeh S}, title = {Cinnamomum Tamala As an Adjuvant Therapy in the Treatment of Major Depressive Disorder: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial With Placebo Control}, journal = {Advances in Integrative Medicine}, volume = {7}, number = {3}, pages = {141-147}, year = {2020} }
RIS	TY - JOUR AU - Ghaffari S AU - Ghobadi A AU - Jamshidi AH AU - Mortazavi SH AU - Naderi S AU - Aqamolaei A AU - Mortezaei A AU - Sahebolzamani E AU - Shamabadi A AU - Jalilvand S AU - Daraei B AU - Shalbafan MR AU - Akhondzadeh S TI - Cinnamomum Tamala As an Adjuvant Therapy in the Treatment of Major Depressive Disorder: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial With Placebo Control JO - Advances in Integrative Medicine VL - 7 IS - 3 SP - 141 EP - 147 PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract